{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:05:28Z","timestamp":1766473528752,"version":"3.48.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Norwegian Government (KLINBEFORSK). The Norwegian Cancer Society. MATRIX. J&J Innovative Medicine. BMS\/Celgene. the Binding Site. GSK."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01407-5","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:16:00Z","timestamp":1766423760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-8577","authenticated-orcid":false,"given":"Frida Bugge","family":"Askeland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7120-5706","authenticated-orcid":false,"given":"Vilhelm Hauge","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lys\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einar","family":"Hauk\u00e5s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Moksnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2323-2578","authenticated-orcid":false,"given":"Anette L.","family":"Eilertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Tsykunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte Dahl","family":"Eiken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1011-138X","authenticated-orcid":false,"given":"Nils Morten","family":"Leknes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Rolke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidar","family":"Stavseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0366-3796","authenticated-orcid":false,"given":"Eivind","family":"Samstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi Fykse","family":"Hallstensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9212-9595","authenticated-orcid":false,"given":"Damian","family":"Szatkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane Aasb\u00f8","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita Smith","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4863","authenticated-orcid":false,"given":"Tobias S.","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-7992","authenticated-orcid":false,"given":"Pegah","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"1407_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1407_CR2","doi-asserted-by":"publisher","first-page":"e23416","DOI":"10.1002\/jcla.23416","volume":"34","author":"X Chen","year":"2020","unstructured":"Chen X, Luo X, Zu Y, Issa HA, Li L, Ye H, et al. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. J Clin Lab Anal. 2020;34:e23416.","journal-title":"J Clin Lab Anal"},{"key":"1407_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00806-w","volume":"13","author":"N Leung","year":"2023","unstructured":"Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13:46.","journal-title":"Blood Cancer J"},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ndt\/gfz211","volume":"36","author":"M Courant","year":"2021","unstructured":"Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dialysis Transplant. 2021;36:482\u201390.","journal-title":"Nephrol Dialysis Transplant"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337\u201341.","journal-title":"Leuk Lymphoma"},{"key":"1407_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.20","volume":"5","author":"W Gonsalves","year":"2015","unstructured":"Gonsalves W, Leung N, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296\u2013e.","journal-title":"Blood Cancer J"},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.clml.2022.04.013","volume":"22","author":"R Sharma","year":"2022","unstructured":"Sharma R, Jain A, Jandial A, Lad D, Khadwal A, Prakash G, et al. Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment. Clin Lymphoma Myeloma Leuk. 2022;22:626\u201334.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ajh.25959","volume":"95","author":"AG Szabo","year":"2020","unstructured":"Szabo AG, Thorsen J, Iversen KF, Hansen CT, Teodorescu EM, Pedersen SB, et al. Clinically-suspected cast nephropathy: a retrospective, national, real-world study. Am J Hematol. 2020;95:1352\u201360.","journal-title":"Am J Hematol"},{"key":"1407_CR9","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.20.00298","volume":"38","author":"F Bridoux","year":"2020","unstructured":"Bridoux F, Arnulf B, Karlin L, Blin N, Rabot N, Macro M, et al. Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy. J Clin Oncol. 2020;38:2647\u201357.","journal-title":"J Clin Oncol"},{"key":"1407_CR10","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos M-V, Zweegman S, et al. EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025:1\u201321."},{"key":"1407_CR11","unstructured":"Agency EM Lenalidomide Accord: EPAR\u2014Product information 2024 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lenalidomide-accord#product-info."},{"key":"1407_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharm. 2007;47:1466\u201375.","journal-title":"J Clin Pharm"},{"key":"1407_CR13","first-page":"86","volume":"8","author":"J Mikhael","year":"2018","unstructured":"Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood. Cancer J. 2018;8:86.","journal-title":"Cancer J"},{"key":"1407_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/hemato1020008","volume":"1","author":"A-M Rasmussen","year":"2020","unstructured":"Rasmussen A-M, Askeland FB, Schjesvold F. The next step for MRD in myeloma? Treating MRD relapse after first line treatment in the REMNANT study. Hemato. 2020;1:8.","journal-title":"Hemato"},{"key":"1407_CR15","doi-asserted-by":"crossref","unstructured":"Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. editors. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006.","DOI":"10.4065\/81.12.1575"},{"key":"1407_CR16","doi-asserted-by":"crossref","unstructured":"Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, et al. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702. Leukemia. 2025:1\u20134.","DOI":"10.1038\/s41375-025-02534-5"},{"key":"1407_CR17","first-page":"2941","volume":"128","author":"T Dejoie","year":"2016","unstructured":"Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood, J Am Soc Hematol. 2016;128:2941\u20138.","journal-title":"Blood, J Am Soc Hematol"},{"key":"1407_CR18","first-page":"2955","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. J Am Soc Hematol. 2016;127:2955\u201362.","journal-title":"J Am Soc Hematol"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24:e293\u2013e311.","journal-title":"Lancet Oncol"},{"key":"1407_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","volume":"59","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59:786\u201394.","journal-title":"Am J Kidney Dis"},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","volume":"6","author":"CA Hutchison","year":"2019","unstructured":"Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6:e217\u2013e28.","journal-title":"Lancet Haematol"},{"key":"1407_CR23","doi-asserted-by":"publisher","first-page":"e101819","DOI":"10.1371\/journal.pone.0101819","volume":"9","author":"K Uttervall","year":"2014","unstructured":"Uttervall K, Duru AD, Lund J, Liwing J, Gahrton G, Holmberg E, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. 2014;9:e101819.","journal-title":"PLoS One"},{"key":"1407_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01407-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:02:13Z","timestamp":1766473333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01407-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01407-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FBA has received honoraria or payments from J&J and Sanofi, and has participated in advisory boards for J&J and Sanofi. EH has received honoraria or payments from J&J and has participated in advisory boards for Sanofi. MM has received honoraria or payments from J&J and AbbVie, and has participated in advisory boards for Sanofi, AbbVie, Shire, and Lilly. ALE has received honoraria or payments from J&J, Bayer, Pfizer, and Incyte; and participated in advisory boards for Sanofi, J&J, Pfizer, and GSK. GT has received honoraria or payments from J&J, Sanofi, SOBI, and Grifols, and has participated in advisory boards for J&J, Sanofi, SOBI, and Grifols. VS has received honoraria or payments from J&J. TSS has received honoraria for lectures and educational material from Takeda, Celgene, Amgen, J&J, AbbVie, and Pfizer; has received consulting fees from BMS, GSK, Sanofi, Pfizer, and Menarini Group; and has participated in advisory boards for Amgen, Celgene, GSK, J&J, Sanofi, and BMS. FS has received grants from Targovax; has received consulting fees from Caedo Therapeutics; has received honoraria\/payment from Amgen, BMS, Takeda, Sanofi, Menarini, AbbVie, J&J, Oncopeptides, and GSK; has participated on advisory boards or data safety monitoring for GSK, Takeda, BMS, J&J, Oncopeptides, Regeneron, Sanofi, XNK Therapeutics, Galapagos, and Pfizer; and is the president of the Nordic Myeloma Study Group (academic group). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}